FDA Warning Letter to R3 Medical Companies (August 2026): Stem Cell and Exosome Enforcement, CGMP Charges, and Criminal Exposure
FDA posted its August 2026 stem cell warning letter to R3 Medical Companies, the enterprise behind R3 Stem Cell and the ReBella product line. Built from facility inspections rather than a website review, the letter charges unapproved drug, unlicensed biologic, and CGMP adulteration violations, cites the company's own social media as evidence, and recites seven years of FDA notice to the same CEO. Former DOJ prosecutors break down what it means for the regenerative medicine industry.
FDA Warning Letters on Exosome Products | Regulatory & Criminal Defense
FDA warning letters to exosome manufacturers cite unapproved drugs, unlicensed biologics, and misbranded products under the FD&C Act and PHS Act. Analysis of enforcement trends from 2024 through 2026, criminal prosecution risks, and the regulatory framework for exosome products. Defense by former senior DOJ officials.